Skip to content

EXPLORATORY RESEARCH FOR CONSTRUCTION AND APPLICATION OF A DATABASE OF THE NORMAL GABAA RECEPTOR BRAIN SPECT TO VISUALIZE NEURONAL LOSS IN NEURODEGENERATIVE DISEASES

EXPLORATORY RESEARCH FOR CONSTRUCTION AND APPLICATION OF A DATABASE OF THE NORMAL GABAA RECEPTOR BRAIN SPECT TO VISUALIZE NEURONAL LOSS IN NEURODEGENERATIVE DISEASES - EXPLORATORY RESEARCH FOR CONSTRUCTION AND APPLICATION OF A DATABASE OF THE NORMAL GABAA RECEPTOR BRAIN SPECT TO VISUALIZE NEURONAL LOSS IN NEURODEGENERATIVE DISEASES

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000028088
Enrollment
13
Registered
2017-07-05
Start date
2017-06-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegenerative diseases such as amyotrophic lateral sclerosis

Interventions

None listed

Sponsors

Department of Neurology, Niigata National Hospital, National Hospital Organization
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: [Normaldatabase creation] 1) Subject is aged between 20 to 60 years old (at the time of consent) 2) Subject is able to undergo necessary tests on designated dates after providing consent 3) Subject has no issues in the neuropsychological exam performed within 3 months of providing consent 4) Subject's MRI and MRA diagnostic imaging, performed within 3 months of providing consent, is age-appropriate and has no issues (although atrophy corresponding to age may be present, it is necessary that ischemic white matter lesion, lacunar infarction of 3 mm or more, cysts, and signal loss of major blood vessels in MRA are not present) 5) Subject himself can provide written consent to participate in this research 6) Subject's neuropsychological exam presents no issues (in MMSE more than 27 points). 7) Subject has been examined by a neurologist, and is confirmed to not have neurological abnormalities (Assessment of lesional distribution) 1) 20 years or older at the time of consent 2) Subjects who can show their willingness to consent (including manifestation of intention by means of communication devices etc.), undergo the informed consent process in the presence of an impartial witness and subject himself provides consent to participate in the research.

Exclusion criteria

Exclusion criteria: [Normaldatabase creation] 1) Subject is a pregnant, is capable of being pregnant, or is breast-feeding 2) Subject has a history of alcohol poisoning or is receiving treatment for it 3) SUbject has a history of epilepsy or is receiving treatment for it 4) Subject is receiving antidepressants, psychotropics, prolonged hypnotic sedatives (including anxiolytics) 5) Subject has a history of mental/neurological diseases that affect cognitive function 6) Subject has a serious complications (liver, kidney disorders and endocrine diseases etc.) 7) Smoker (more than 20 years having one-packet and more per day) [Assessment of lesional distribution] 1) ubject is a pregnant, is capable of being pregnant, or is breast-feeding 2) Subject has a serious complications (liver, kidney disorders and endocrine diseases etc.)

Design outcomes

Primary

MeasureTime frame
Projection data of IMZ SPECT

Secondary

MeasureTime frame
Head MRI(T1,T2,FLAIR,sDWI,T2*,3D-T1,MRA)

Countries

Japan

Contacts

Public ContactMasanobu Tobinaga

Niigata National Hospital, National Hospital Organization Department of Neurology

m.tobinaga@niigata-nh.go.jp0257-22-2126

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026